The proportion of patients with a response of 0 or 1 on the modified investigator 's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept : in the ERASURE study , the rates were 65.3 % with 300 mg of secukinumab , 51.2 % with 150 mg of secukinumab , and 2.4 % with placebo ; in the FIXTURE study , the rates were 62.5 % with 300 mg of secukinumab , 51.1 % with 150 mg of secukinumab , 27.2 % with etanercept , and 2.8 % with placebo ( P < 0.001 for each secukinumab dose vs. comparators ) .